StockWatch: Insmed Jumps on Report of Takeover Interest by Sanofi, as Analysts Conclude a Deal Would Make Sense
Twenty-one months after Insmed (Nasdaq: INSM) made GEN‘s A-List highlighting Top 10 Takeover Targets of 2025, the developer of respiratory, immunology & inflammation, neuro, and rare disease drugs may really be on the verge of finding a buyer—at least according to a published report that sparked a 21.5% surge in the company’s shares this past week.
Bloomberg News cited unnamed sources in reporting that Sanofi (Euronext Paris: SAN and Nasdaq: SNY) was weighing whether to acquire Insmed, in a potential blockbuster deal that the news outlet and others speculated could be biopharma’s largest merger-and-acquisition (M&A) deal since 2023, when Pfizer (NYSE: PFE), then flush with COVID-19 vaccine cash, shelled out $43 billion for Seagen, overcoming fears that Washington would block the deal on antitrust grounds.
Behind the speculation is Insmed’s sizeable market capitalization (share price times the number of outstanding shares), which climbed 23% from about $26.3 billion before Sanofi surfaced as a would-be buyer to $32.3 billion as of Friday. Over the past month, Insmed’s stock has soared 48%, buoyed by strong third-quarter results and rising sales projections for its two marketed drugs, Brinsupri® (brensocatib) and Arikayce® (amikacin liposome inhalation suspension).
Insmed and Sanofi declined to comment on the report, which said talks were ongoing, that weeks could pass before a deal emerges, that Sanofi may never reach an agreement, and that other bidders may emerge.
However, Insmed’s investors appeared to believe the story enough to send the company’s shares jumping nearly 21% from $119.80 on Wednesday to $144.46 on Thursday, after peaking at $149.07 and a 24% gain. Shares flattened Friday, then dipped 2% to $141.33 to finish the week.
“A rational fit”
“While we cannot speak to the validity of the report, Sanofi has been seen as a rational fit given the overlapping respiratory franchises,” commented Matt Phipps, PhD, partner and group head of biotechnology equity research with William Blair, and three colleagues in a research note.
Phipps’ group and analysts at other firms reason that Insmed’s marketed drugs and pipeline would complement the treatments and pipeline candidates of Sanofi—especially in respiratory disease, where Sanofi and Regeneron Pharmaceuticals (Nasdaq: REGN) co-market the blockbuster drug Dupixent® (dupilumab).
Dupixent is approved for nine indications across respiratory diseases, including chronic obstructive pulmonary disease (COPD) as well as skin and gastrointestinal disorders. Sanofi recorded $6.5 billion in global sales for Dupixent during January−September 2026, up 35% from a year ago, and the drug accounts for more than one-third of Sanofi’s total revenues.
“Given that SNY has a strong focus in immunology, with [Dupixent] being approved in a variety of pulmonary/respiratory indications—such as COPD and asthma—we think there could be a strong rationale and commercial synergies to add INSM’s assets to the portfolio,” commented Leonid Timashev, PhD, director and biotechnology analyst with RBC Capital Markets, in a research note reported by Investor’s Business Daily.
Added Joseph P. Schwartz, senior managing director, rare diseases, and a senior research analyst with Leerink Partners: “SNY already has a strong pulmonary commercial footprint, especially in COPD, which could unlock the next stage of growth for Brinsupri in co-morbid patients.”
But Dupixent faces a “patent cliff” loss of exclusivity for its key patents in 2031, and Sanofi CEO Belén Garijo—who took office May 1, succeeding Paul Hudson—has made it a priority to rebuild the company’s pipeline and portfolio of marketed treatments.
Clinical failures and successes
That task has been made more urgent by the failure of several Sanofi drug candidates in clinical trials. They include:
- Amlitelimab, an OX40-ligand monoclonal antibody whose development in moderate-to-severe atopic dermatitis at Sanofi ended in July. The drug remains in Phase IIa/b development in celiac disease.
- Balinatunfib, an oral tumor necrosis factor (TNF) inhibitor whose development Sanofi ended in July by terminating studies in Crohn’s disease and ulcerative colitis, after an interim analysis showed the drug was unlikely to reach expected efficacy. Since last year, Sanofi ended development of balinatufib in moderate-to-severe plaque psoriasis and rheumatoid arthritis.
- Itepekimab, a monoclonal antibody targeting interleukin-33 (IL-33), ended development in COPD and chronic rhinosinusitis after the second quarter, following a company assessment of the competitive landscape and mixed data from its Phase III studies.
Insmed, by contrast, has shown success commercializing its treatments following clinical successes. The company made history last year when the FDA approved Brinsupri, sold in 10 mg and 25 mg tablets, as the first drug authorized to treat non-cystic fibrosis bronchiectasis (NCFB). Brinsupri accounted for nearly three-fourths (73%) or $917.1 million of the $1.256 billion in total revenue reported by Insmed for the first three quarters of this year, 29% above the second quarter and multiples above the $28.1 million the drug racked up in Q3 2025.
Total revenue during Q1−Q3 2026 is more than triple (267%) above the $342.6 million garnered during January−September 2025.
Based on its strong Q3 numbers, Insmed earlier this month raised the low end of its full-year revenue guidance range to investors on Brinsupri to $1.35 billion from $1.25 billion, keeping the high end at $1.4 billion. Those numbers are well above the company’s initial 2026 Brinsupri revenue forecast of at least $1 billion.
“Only just begun”
“We have literally only just begun to see the benefit Brinsupri will bring to patients,” Insmed chair and CEO Will Lewis told investors on the company’s quarterly earnings call.
Lewis said that when Q4 2025 revenue is added to Q1−Q3 2026, Brinsupri has already achieved “blockbuster” status of more than $1 billion in revenue in its first four full quarters of launch.
“We believe we have only scratched the surface of the potential addressable patients who may benefit from this first-ever approved foundational medicine in bronchiectasis,” Lewis said. “While we have treated tens of thousands of patients in the first year, there remain hundreds of thousands of patients already diagnosed and waiting, with potentially millions more who may benefit.”
Last time Insmed offered analysts a figure for its initial U.S. target population for Brinsupri, Lewis told analysts, the company cited “500,000 or 550,000” overall diagnosed non-cystic fibrosis bronchiectasis patients in the United States, adding: “That was three years ago. So we certainly believe it has grown since then.”
Insmed no longer reports specific quarterly numbers of new patient starts as it did during Brinsupri’s first year on the market, including approximately 2,550 new starts during the third quarter of 2025.
Jefferies, however, has modeled as many as approximately 8,000 for the third quarter. “Brinsupri new starts will continue to increase into 2027,” Faisal Khurshid, an equity analyst with the firm, wrote in a research note just before the Sanofi-Insmed news report, summarizing comments attributed to Lewis during a meeting and dinner with Jefferies analysts.
“As mgmt [management] suggested, ‘maybe a couple hundred’ growth in new starts per qtr going forward,” Faisal added.
Brinsupri became the company’s second drug to reach the market, after Arikayce won agency approval in 2018 as a treatment for mycobacterium avium complex (MAC) lung disease. Arikayce has racked up $338.8 million during Q1−Q3 2026, up 8% from $314.5 million a year earlier, with revenue guidance also raised at the low end to $460 million from $450 million, while the company has maintained the high end at $470 million.
Three key assets
Phipps said Insmed carries with it three key assets—not just Brinsupri and Arikayce, but also its late-stage pipeline candidate Treprostinil Palmitil Inhalation Powder (TPIP), which is in Phase III studies for three indications: Pulmonary hypertension associated with interstitial lung disease (PH-ILD); pulmonary arterial hypertension (PAH); and progressive pulmonary fibrosis (PPF). TPIP is in Phase II development for idiopathic pulmonary fibrosis (IPF).
In PH-ILD, Insmed said in reporting Q3 results that it had enrolled more than 35% of patients in the Phase III PALM-ILD trial (NCT07179380) and expects to complete enrollment in the first half of 2028. In PAH, Insmed enrolled its first patient in the Phase III PALM-PAH study (NCT07481981) in July, while in PPF, the company launched the Phase III PALM-PPF study (NCT07805785) in September.
Insmed added that it expects to launch a Phase III trial assessing TPIP in IPF patients during the first half of 2027.
“We continue to believe Insmed has long-term upside based on the potential of the three key assets,” Phipps asserted.
Key challenge
Phipps and Schwartz said a key challenge to a Sanofi-Insmed deal getting done revolves around how much the buyer would have to spend.
“Overall, we believe the biggest questions are if Sanofi has the capacity for the deal, and at what price Insmed management would be willing to sell,” Phipps wrote. “A big question is whether Sanofi can truly afford an acquisition in the $40 billion range with current net debt of about €12 billion [about $13.2 billion]. Some investors have speculated whether the Insmed assets could be added to Sanofi’s joint venture with Regeneron to provide additional capital to reach necessary valuations.”
Added Schwartz: “Coming to an agreement on price is a key question in our view—INSM looks cheap right now relative to peak sales guidance of >$14B, but assigning a deal premium to [Wednes]day’s ~$120 stock price would put a transaction in the ~$38−$43B range, whereas SNY said in Jan ’26 they have €15B [about $16.5 billion] to spend on deals so it seems that INSM would require further leverage,” Schwartz wrote.
“It is unclear how much SNY values TPIP since it falls outside its core programs,” Schwartz added.
As for potential other bidders, Schwartz said two other pharma giants would be “logical suitors” for TPIP—Merck & CO. (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ). A third pharma, AstraZeneca (London, Nasdaq Stockholm, and NYSE: AZN), could emerge as a would-be buyer interested in Brinsupri, he added.
“We see several reasons that could make INSM strategically interesting to one or more larger players,” Jessica Fye, a managing director and senior equity research analyst with J.P. Morgan, wrote in a research note. “1) meaningful immediate revenue contribution, 2) large, needle-moving peak potential, 3) long durability on Brinsupri, which is just 1 year into its launch, and 4) pipeline value, particularly in Phase III asset TPIP, which we see as a high-probability of success multi-billion-dollar asset in its own right. Together, we think these features make INSM a scarce asset that could be attractive to multiple large companies,” Fye added.
Leaders and laggards
Anthropic (Nasdaq: ANT) shares climbed 17% from their initial public offering (IPO) price to $97.17 on Thursday in the largest-ever IPO by amount raised. The developer of the Claude family of large language models and other artificial intelligence (AI) tools has included expanding its growing life sciences presence among uses for the staggering $81 billion in proceeds raised by selling 1,103,351,354 shares at $83. Some buyers sold 23,648,646 shares to others, for a total of 1.127 billion Class A shares sold. Underwriters exercised in full their option to buy another 147 million additional Class A shares from Anthropic at the IPO price. Anthropic also closed concurrently on the sale of 313,253,007 shares of Class N common stock via private placement to Advanced Micro Devices (Nasdaq: AMD), Broadcom (Nasdaq: AVGO), Google (owned by Alphabet [Nasdaq: GOOG]), Micron Technology (Nasdaq: MU), Microsoft (Nasdaq: MSFT), Nvidia (Nasdaq: NVDA), and an investment entity of Taiwan Semiconductor Manufacturing Company (TSMC; Taiwan Stock Exchange: 2330 and NYSE: TSM). Anthropic gave up part of its gains Friday, sinking 8.5% to $88.91 on investor profit-taking and a broader selloff of AI and tech stocks.
Cue Biopharma (Nasdaq: CUE) shares plummeted 80% from $14.10 to $2.83 Tuesday, after the immunological drug developer reported third-quarter results after the close of markets on November 16. Cue finished Q3 with a $50 million net loss, nearly seven times the $7.4 million net loss of Q3 2025. The company cited costs associated with the startup and launch of clinical development, and non-cash stock-based compensation expenses related to long term, performance-based, companywide incentive equity grants made following Cue’s pipeline and leadership overhauls during the second quarter. Cue emphasized positive developments such as the start of dosing in its Phase I trial assessing its lead autoimmune candidate CUE-401, a dual IL-2 and TGF-beta agonist, and additional positive data from a Phase II trial of CUE-221 in chronic spontaneous urticaria (CSU). Cue licenses CUE-221 from Ascendant Health Sciences, whose related company, Genesis Life Sciences, conducted the Phase II trial in China.
Nvidia (Nasdaq: NVDA) shares skidded 23% this past week, from $162.85 on November 13 to $125.53 at Friday’s closing bell, on news that included a report Tuesday by The Wall Street Journal that the U.S. Securities and Exchange Commission (SEC) had begun to investigate the company, days after co-founder and CEO Jensen Huang suddenly resigned. On Friday, Reuters reported that SEC enforcement staffers were focusing on potential accounting issues—news that triggered a 14% drop from Thursday’s close of $145.98. Since its record closing price of $239.24 on October 6, Nvidia stock has lost nearly half (47%) of its market value—an eye-popping $2.7 trillion, from some $5.77 trillion to about $3.03 trillion. However, for the quarter ended October 25, Nvidia reported record revenue of $115.8 billion Tuesday after market close, up 103% year-over-year.
Sellas Life Sciences Group (Nasdaq: SLS) shares more than doubled, rocketing 156% from $7.47 to $19.15 Tuesday after the cancer therapeutics developer announced positive topline results from the pivotal randomized Phase III REGAL trial (NCT04229979) assessing galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The trial met its primary endpoint, with GPS demonstrating a statistically significant and clinically meaningful reduction in risk of death by 41%, with median overall survival of 24.0 months vs. 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035). Sellas plans to meet with the FDA to discuss an accelerated filing strategy and advance preparations for a Biologics License Application (BLA) submission for GPS. Sellas shares tumbled 29% to $13.66 between Wednesday and Friday after closing an underwritten public offering of 13,269,231 shares—including the exercise in full by underwriters of their option to buy 1,730,769 additional shares—at $13 per share, a price many investors viewed as too low. Sellas’s offering generated an estimated $161.8 million in net proceeds.
The post StockWatch: Insmed Jumps on Report of Takeover Interest by Sanofi, as Analysts Conclude a Deal Would Make Sense appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
